Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Acquired by Sumitomo Mitsui DS Asset Management Company Ltd

Sumitomo Mitsui DS Asset Management Company Ltd raised its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 2.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 55,588 shares of the medical research company’s stock after buying an additional 1,213 shares during the quarter. Sumitomo Mitsui DS Asset Management Company Ltd’s holdings in Thermo Fisher Scientific were worth $28,919,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also modified their holdings of TMO. AMF Tjanstepension AB acquired a new position in shares of Thermo Fisher Scientific during the third quarter worth about $42,409,000. Artemis Investment Management LLP grew its position in Thermo Fisher Scientific by 103.1% during the third quarter. Artemis Investment Management LLP now owns 16,877 shares of the medical research company’s stock worth $10,440,000 after buying an additional 8,566 shares during the period. Brookstone Capital Management grew its holdings in shares of Thermo Fisher Scientific by 3.1% in the 3rd quarter. Brookstone Capital Management now owns 2,558 shares of the medical research company’s stock worth $1,582,000 after acquiring an additional 76 shares during the period. First PREMIER Bank increased its position in shares of Thermo Fisher Scientific by 344.4% in the third quarter. First PREMIER Bank now owns 160 shares of the medical research company’s stock valued at $99,000 after buying an additional 124 shares in the last quarter. Finally, Daymark Wealth Partners LLC lifted its holdings in shares of Thermo Fisher Scientific by 14.5% in the third quarter. Daymark Wealth Partners LLC now owns 709 shares of the medical research company’s stock valued at $439,000 after purchasing an additional 90 shares in the last quarter. 89.23% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Thermo Fisher Scientific

In related news, CFO Stephen Williamson sold 9,825 shares of Thermo Fisher Scientific stock in a transaction dated Tuesday, February 4th. The stock was sold at an average price of $585.59, for a total value of $5,753,421.75. Following the completion of the transaction, the chief financial officer now directly owns 27,296 shares of the company’s stock, valued at $15,984,264.64. The trade was a 26.47 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $530.26, for a total transaction of $5,302,600.00. Following the completion of the sale, the chief executive officer now owns 111,192 shares of the company’s stock, valued at $58,960,669.92. The trade was a 8.25 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 20,125 shares of company stock valued at $11,231,699. 0.34% of the stock is currently owned by company insiders.

Thermo Fisher Scientific Trading Down 1.8 %

Shares of Thermo Fisher Scientific stock opened at $571.75 on Friday. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.66 and a quick ratio of 1.29. The company’s fifty day moving average price is $545.51 and its two-hundred day moving average price is $571.95. Thermo Fisher Scientific Inc. has a 52-week low of $493.30 and a 52-week high of $627.88. The firm has a market capitalization of $218.70 billion, a PE ratio of 34.59, a price-to-earnings-growth ratio of 4.06 and a beta of 0.77.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Thursday, January 30th. The medical research company reported $6.10 earnings per share for the quarter, beating analysts’ consensus estimates of $5.94 by $0.16. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. On average, analysts expect that Thermo Fisher Scientific Inc. will post 23.29 EPS for the current year.

Thermo Fisher Scientific declared that its board has authorized a stock repurchase program on Friday, November 15th that authorizes the company to repurchase $4.00 billion in shares. This repurchase authorization authorizes the medical research company to buy up to 2% of its stock through open market purchases. Stock repurchase programs are generally a sign that the company’s board of directors believes its stock is undervalued.

Analysts Set New Price Targets

A number of research analysts have issued reports on TMO shares. Wells Fargo & Company upped their target price on shares of Thermo Fisher Scientific from $660.00 to $680.00 and gave the company an “overweight” rating in a report on Friday, January 31st. StockNews.com raised shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a report on Tuesday, January 14th. Bernstein Bank lifted their price objective on shares of Thermo Fisher Scientific from $565.00 to $625.00 and gave the company a “market perform” rating in a research report on Tuesday, October 22nd. Robert W. Baird dropped their target price on shares of Thermo Fisher Scientific from $632.00 to $622.00 and set an “outperform” rating on the stock in a report on Thursday, October 24th. Finally, Sanford C. Bernstein raised shares of Thermo Fisher Scientific from a “market perform” rating to an “outperform” rating and set a $630.00 price objective for the company in a research note on Friday, January 10th. Four investment analysts have rated the stock with a hold rating and nineteen have issued a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $658.00.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.